With the Johnson & Johnson vaccine paused in the United States, the European Union drug regulator found that the benefits outweigh the rare risk of blood clots.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register. By continuing to use this site, you are consenting to our use of cookies.